<DOC>
	<DOC>NCT02647359</DOC>
	<brief_summary>This is a Phase 2, randomized, double-masked, placebo-controlled study of ataluren in patients with aniridia caused by a nonsense mutation. Patients will receive masked study drug for 48 weeks followed by open-label ataluren for another 48 weeks. Safety and efficacy will be assessed.</brief_summary>
	<brief_title>Study of Ataluren in Patients With Aniridia</brief_title>
	<detailed_description />
	<mesh_term>Aniridia</mesh_term>
	<criteria>Age ≥2 years Body weight ≥12 kg Documentation of the presence of a nonsense mutation in 1 allele of the PAX6 gene Clinical diagnosis of aniridia 20/200 or worse visual acuity in the better eye with best correction. Subjects who are monocular. Subjects with a history of complicated ocular surgery</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>